- Home
- ESPR vs ORGO Comparison
ESPR vs ORGO Comparison
Compare ESPR & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ORGO
- Stock Information
- Founded
- ESPR 2008
- ORGO 1985
- Country
- ESPR United States
- ORGO United States
- Employees
- ESPR N/A
- ORGO N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ORGO Health Care
- Exchange
- ESPR Nasdaq
- ORGO Nasdaq
- Market Cap
- ESPR 534.3M
- ORGO 620.3M
- IPO Year
- ESPR 2013
- ORGO N/A
- Fundamental
- Price
- ESPR $2.55
- ORGO $4.17
- Analyst Decision
- ESPR Buy
- ORGO Buy
- Analyst Count
- ESPR 6
- ORGO 3
- Target Price
- ESPR $6.50
- ORGO $7.33
- AVG Volume (30 Days)
- ESPR 7.0M
- ORGO 832.5K
- Earning Date
- ESPR 11-06-2025
- ORGO 11-06-2025
- Dividend Yield
- ESPR N/A
- ORGO N/A
- EPS Growth
- ESPR N/A
- ORGO N/A
- EPS
- ESPR N/A
- ORGO N/A
- Revenue
- ESPR $268,125,000.00
- ORGO $429,531,000.00
- Revenue This Year
- ESPR $13.05
- ORGO $2.51
- Revenue Next Year
- ESPR N/A
- ORGO $25.45
- P/E Ratio
- ESPR N/A
- ORGO N/A
- Revenue Growth
- ESPR N/A
- ORGO N/A
- 52 Week Low
- ESPR $0.69
- ORGO $2.61
- 52 Week High
- ESPR $3.94
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- ESPR 47.71
- ORGO 37.53
- Support Level
- ESPR $2.35
- ORGO $4.12
- Resistance Level
- ESPR $3.41
- ORGO $4.40
- Average True Range (ATR)
- ESPR 0.18
- ORGO 0.24
- MACD
- ESPR -0.03
- ORGO -0.06
- Stochastic Oscillator
- ESPR 9.79
- ORGO 12.92
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.